Article
Gastroenterology & Hepatology
Christina M. Brennan, Sandeep Nadella, Xiang Zhao, Richard J. Dima, Nicole Jordan-Martin, Breanna R. Demestichas, Sam O. Kleeman, Miriam Ferrer, Eva Carlotta von Gablenz, Nicholas Mourikis, Michael E. Rubin, Harsha Adnani, Hassal Lee, Taehoon Ha, Soma Prum, Cheryl B. Schleicher, Sharon S. Fox, Michael G. Ryan, Christina Pili, Gary Goldberg, James M. Crawford, Sara Goodwin, Xiaoyue Zhang, Jonathan B. Preall, Ana S. H. Costa, Joseph Conigliaro, Joseph R. Masci, Jie Yang, David A. Tuveson, Kevin J. Tracey, Tobias Janowitz
Summary: This study assessed the effect of famotidine on inflammation and symptomatic recovery in patients with mild to moderate COVID-19. The results showed that famotidine led to earlier resolution of symptoms and inflammation without reducing anti-SARS-CoV-2 immunity. Additional randomized trials are needed to confirm these findings.
Article
Medicine, General & Internal
Jong-Mu Sun, Lin Shen, Manish A. Shah, Peter Enzinger, Antoine Adenis, Toshihiko Doi, Takashi Kojima, Jean-Philippe Metges, Zhigang Li, Sung-Bae Kim, Byoung Chul Cho, Wasat Mansoor, Shau-Hsuan Li, Patrapim Sunpaweravong, Maria Alsina Maqueda, Eray Goekkurt, Hiroki Hara, Luis Antunes, Christos Fountzilas, Akihito Tsuji, Victor Castro Oliden, Qi Liu, Sukrut Shah, Pooja Bhagia, Ken Kato
Summary: This study aimed to evaluate the antitumor activity of pembrolizumab plus chemotherapy versus chemotherapy alone as first-line treatment in advanced esophageal cancer. Results showed that pembrolizumab plus chemotherapy significantly improved overall survival and progression-free survival in patients with esophageal squamous cell carcinoma.
Article
Critical Care Medicine
Phillip D. Monk, Richard J. Marsden, Victoria J. Tear, Jody Brookes, Toby N. Batten, Marcin Mankowski, Felicity J. Gabbay, Donna E. Davies, Stephen T. Holgate, Ling-Pei Ho, Tristan Clark, Ratko Djukanovic, Tom M. A. Wilkinson
Summary: The study evaluated the efficacy and safety of using interferon beta-1a to treat COVID-19, with results showing that patients who received treatment had higher and faster recovery rates, providing potential evidence for further clinical trials.
LANCET RESPIRATORY MEDICINE
(2021)
Article
Medicine, General & Internal
Summary: This study presents the final results of the Solidarity trial and meta-analyses of mortality in relevant trials. The findings suggest that remdesivir does not have a significant effect on COVID-19 patients who are already on ventilators. However, it does have a small effect against death or progression to ventilation in other hospitalized patients.
Article
Medicine, General & Internal
Mark N. Polizzotto, Jacqueline Nordwall, Abdel G. Babiker, Andrew Phillips, David M. Vock, Nnakelu Eriobu, Vivian Kwaghe, Roger Paredes, Lourdes Mateu, Srikanth Ramachandruni, Rajeev Narang, Manua K. Jain, Susana M. Lazarte, Jason Baker, Anne E. P. Frosch, Garyfallia Poulakou, Konstantinos N. Syrigos, Gretchen S. Amoczy, Natalie A. McBride, Philip A. Robinson, Farjad Sarafian, Sanjay Bhagani, I. Lassan S. Taha, Thomas Benfield, Sean T. H. Liu, Anastasia Antoniadou, Jens Ulrik Staehr Jensen, Ioannis Kalomenidis, Adityo Susilo, Prasetyo Hariadi, Tomas O. Jensen, Jose Luis Morales-Rull, Marie Helleberg, Sreenath Meegada, Isik S. Johansen, Daniel Canario, Eduardo Fernandez-Cruz, Simeon Metallidis, Amish Shah, Aki Sakurai, Nikolaus G. Koulouris, Robin Trounan, Amy C. Weintrob, Dania Podlekareva, Usman Hadi, Kathryn M. Lloyd, Birgit Thorup Roge, Sho Saito, Kelly Sweenis, Jakob J. Malin, Christoph Luebbert, Jose Munoz, Matthew J. Cummings, Marcelo H. Losso, Dan Turner, Kathryn Shaw-Saliba, Robin Dewar, Helene Highbarger, Pertine Lallemand, Tauseef Rehman, Norman Gerry, Dona Arlinda, Christina C. Chang, Birgit Grund, Michael R. Holbrook, Horace P. Holley, Fleur Hudson, Laura A. McNay, Daniel D. Murray, Sarah L. Pett, Megan Shaughnessy, Mary C. Smolslcis, Giota Touloumi, Mary F. Wright, Mittie K. Doyle, Sharon Popik, Christine Hall, Roshan Ramanathan, Huyen Cao, Elsa Mondou, Todd Willis, Joseph Thakuria, Leman Yel, Elizabeth Liggs, Virginia L. Kan, Jens D. Lundgren, James D. Neaton, H. Clifford Lane
Summary: Passive immunotherapy using hyperimmune intravenous immunoglobulin (hIVIG) derived from recovered donors is a potential therapy for COVID-19. However, this international randomized controlled trial found that hIVIG did not demonstrate efficacy among hospitalized COVID-19 patients when administered with standard care including remdesivir.
Article
Medicine, General & Internal
Raymond Hang Wun Li, Sue Seen Tsing Lo, Kristina Gemzell-Danielsson, Carol Ho Yi Fong, Pak Chung Ho, Ernest Hung Yu Ng
Summary: This study found that co-administration of oral piroxicam 40 mg with levonorgestrel improved the efficacy of emergency contraception. The use of piroxicam could be considered in clinical settings where levonorgestrel emergency contraception is the chosen option.
Article
Infectious Diseases
Florence Ader, Maude Bouscambert-Duchamp, Maya Hites, Nathan Peiffer-Smadja, Julien Poissy, Drifa Belhadi, Alpha Diallo, Minh-Patrick Le, Gilles Peytavin, Therese Staub, Richard Greil, Jeremie Guedj, Jose-Artur Paiva, Dominique Costagliola, Yazdan Yazdanpanah, Charles Burdet, France Mentre
Summary: A study conducted in COVID-19 patients admitted to hospital and requiring oxygen support found that remdesivir did not show significant clinical benefits compared to standard care alone.
LANCET INFECTIOUS DISEASES
(2022)
Article
Respiratory System
Pradeesh Sivapalan, Charlotte Suppli Ulrik, Therese Sophie Lapperre, Rasmus Dahlin Bojesen, Josefin Eklof, Andrea Browatzki, Jon Torgny Wilcke, Vibeke Gottlieb, Kjell Erik Julius Hakansson, Casper Tidemandsen, Oliver Tupper, Howraman Meteran, Christina Bergsoe, Eva Brondum, Uffe Bodtger, Daniel Bech Rasmussen, Sidse Graff Jensen, Lars Pedersen, Alexander Jordan, Helene Prieme, Christian Soborg, Ida E. Steffensen, Dorthe Hogsberg, Tobias Wirenfeldt Klausen, Martin Steen Frydland, Peter Lange, Asger Sverrild, Muhzda Ghanizada, Filip K. Knop, Tor Biering-Sorensen, Jens D. Lundgren, Jens-Ulrik Staehr Jensen
Summary: The combination of azithromycin and hydroxychloroquine did not improve survival or length of hospitalisation in patients with COVID-19.
EUROPEAN RESPIRATORY JOURNAL
(2022)
Review
Critical Care Medicine
Alain Amstutz, Benjamin Speich, France Mentre, Corina Silvia Rueegg, Drifa Belhadi, Lambert Assoumou, Charles Burdet, Srinivas Murthy, Lori Elizabeth Dodd, Yeming Wang, Kari A. O. Tikkinen, Florence Ader, Maya Hites, Maude Bouscambert, Mary Anne Trabaud, Mike Fralick, Todd C. Lee, Ruxandra Pinto, Andreas Barratt-Due, Fridtjof Lund-Johansen, Fredrik Mueller, Olli P. O. Nevalainen, Bin Cao, Tyler Bonnett, Alexandra Griessbach, Ala Taji Heravi, Christof Schonenberger, Perrine Janiaud, Laura Werlen, Soheila Aghlmandi, Stefan Schandelmaier, Yazdan Yazdanpanah, Dominique Costagliola, Inge Christoffer Olsen, Matthias Briel
Summary: This systematic review and meta-analysis assessed the benefits and harms of remdesivir compared to placebo or usual care in COVID-19 patients hospitalized. The study found that remdesivir reduced mortality in patients who required no or conventional oxygen support but did not have enough evidence for patients on ventilators.
LANCET RESPIRATORY MEDICINE
(2023)
Article
Critical Care Medicine
Zelalem Temesgen, Charles D. Burger, Jason Baker, Christopher Polk, Claudia R. Libertin, Colleen F. Kelley, Vincent C. Marconi, Robert Orenstein, Victoria M. Catterson, William S. Aronstein, Cameron Durrant, Dale Chappell, Omar Ahmed, Gabrielle Chappell, Andrew D. Badley
Summary: The LIVE-AIR trial investigated the efficacy and safety of Lenezilumab, a GM-CSF neutralising monoclonal antibody, in treating COVID-19. The results showed that Lenezilumab significantly improved survival without invasive mechanical ventilation in hospitalized patients with COVID-19, with a safety profile similar to that of placebo.
LANCET RESPIRATORY MEDICINE
(2022)
Article
Respiratory System
Carlo Salvarani, Marco Massari, Massimo Costantini, Domenico Franco Merlo, Gabriella Lucia Mariani, Pierluigi Viale, Stefano Nava, Giovanni Guaraldi, Giovanni Dolci, Luca Boni, Luisa Savoldi, Paolo Bruzzi, Caterina Turra, Mariagrazia Catanoso, Anna Maria Marata, Chiara Barbieri, Annamaria Valcavi, Francesca Franzoni, Silvio Cavuto, Giorgio Mazzi, Romina Corsini, Fabio Trapani, Alessandro Bartoloni, Emanuela Barisione, Giulia Jole Burastero, Angelo Pan, Walter Inojosa, Raffaele Scala, Cecilia Burattini, Fabrizio Luppi, Mauro Codeluppi, Kamal Eldin Tarek, Giovanni Cenderello, Mario Salio, Giuseppe Foti, Roberto Dongilli, Gianluigi Bajocchi, Emanuele Alberto Negri, Giacomo Ciusa, Giacomo Fornaro, Ilaria Bassi, Lorenzo Zammarchi, Teresita Aloe, Nicola Facciolongo
Summary: This study evaluated the efficacy and safety of pulse intravenous methylprednisolone in COVID-19 pneumonia patients, and found no significant benefit compared to standard treatment. There were no significant differences in hospital discharge time, survival rates, or overall mortality between the two groups, indicating limited effectiveness of pulse methylprednisolone therapy in treating COVID-19 pneumonia.
EUROPEAN RESPIRATORY JOURNAL
(2022)
Article
Orthopedics
C. R. Davis, C. D. Ruediger, K. A. Dyer, S. Lester, S. W. Graf, F. P. B. Kroon, S. L. Whittle, C. L. Hill
Summary: The study investigated the effects of 1 mg daily colchicine vs. placebo on hand pain and function in older adults with hand osteoarthritis over 12 weeks. It was found that colchicine did not significantly reduce pain, tender and swollen joint count, or increase grip strength in symptomatic hand osteoarthritis. The results do not support the use of colchicine in hand osteoarthritis.
OSTEOARTHRITIS AND CARTILAGE
(2021)
Article
Oncology
Matthew J. Matasar, Marcelo Capra, Muhit Ozcan, Fangfang Lv, Wei Li, Eduardo Yanez, Katya Sapunarova, Tongyu Lin, Jie Jin, Wojciech Jurczak, Aryan Hamed, Ming-Chung Wang, Ross Baker, Igor Bondarenko, Qingyuan Zhang, Jifeng Feng, Klaus Geissler, Mihaela Lazaroiu, Guray Saydam, Arpad Szomor, Krimo Bouabdallah, Rinat Galiulin, Toshiki Uchida, Lidia Mongay Soler, Anjun Cao, Florian Hiemeyer, Aruna Mehra, Barrett H. Childs, Yuankai Shi, Pier Luigi Zinzani
Summary: Copanlisib plus rituximab significantly improved progression-free survival in patients with relapsed indolent non-Hodgkin lymphoma compared with placebo plus rituximab, with the most common grade 3-4 adverse events being hyperglycemia and hypertension.
Article
Medicine, General & Internal
Robin Kate Kelley, Makoto Ueno, Changhoon Yoo, Richard S. Finn, Junji Furuse, Zhenggang Ren, Thomas Yau, Heinz-Josef Klumpen, Stephen L. Chan, Masato Ozaka, Chris Verslype, Mohamed Bouattour, Joon Oh Park, Olga Barajas, Uwe Pelzer, Juan W. Valle, Li Yu, Usha Malhotra, Abby B. Siegel, Julien Edeline, Arndt Vogel
Summary: This study examined the efficacy of adding the immune checkpoint inhibitor pembrolizumab to the standard chemotherapy regimen for advanced biliary tract cancer. The results showed that the combination treatment significantly improved overall survival compared to chemotherapy alone.
Article
Infectious Diseases
James Welker, Juan D. Pulido, Andrew T. Ca Tarizaro, Carlos D. Malvestutto, Zihai Li, Jona Than B. Cohen, Eric D. Whitman, Dana Byrne, Olivia K. Giddings, Jordan E. Lake, Joel Chua, Ella Li, Flan Chen, Xiang Zhou, Kun He, Davis Gates, Amarjot Kaur, Jamie Chen, Hung-Yen Chou, Martin Devenport, Raymond Tommy, Shyamasundaran Kottilil, Yang Liu, Pan Zheng
Summary: CD24Fc is well-tolerated and accelerates clinical improvement in hospitalised adults with COVID-19 receiving oxygen support.
LANCET INFECTIOUS DISEASES
(2022)
Article
Public, Environmental & Occupational Health
Sean Wei Xiang Ong, Pooja Rao, Wei Xin Khong, Victor Yi Fa Ong, Prakki Sai Rama Sridatta, Natascha May Thevasagayam, Benjamin Choon Heng Ho, Brenda Sze Peng Ang, Partha Pratim De, Oon Tek Ng, Kalisvar Marimuthu
Summary: Using whole-genome sequencing, we investigated the transmission of CRAB and found that it was widespread in the cardiac care unit, possibly related to environmental contamination. Based on these findings, we implemented measures to enhance environmental hygiene and reduce the spread of CRAB.
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
(2023)
Article
Infectious Diseases
Patricia Schirmer, Aditya Sharma, Cynthia Lucero-Obusan, Gina Oda, Mark Holodniy
Summary: The study evaluated the adherence to CDC guidelines for repeat chlamydia/gonorrhea testing and testing for HIV/syphilis in the US Veterans Health Administration. The results showed that nearly two-thirds of patients did not receive recommended repeat testing, and nearly one-third were not tested for HIV/syphilis. Additional education on CDC-recommended sexually transmitted infection guidelines and testing recommendations may be beneficial for healthcare providers in the Veterans Health Administration.
SEXUALLY TRANSMITTED DISEASES
(2023)
Article
Immunology
Angela R. Branche, Nadine G. Rouphael, Cecilia Losada, Lindsey R. Baden, Evan J. Anderson, Anne F. Luetkemeyer, David J. Diemert, Patricia L. Winokur, Rachel M. Presti, Angelica C. Kottkamp, Ann R. Falsey, Sharon E. Frey, Richard Rupp, Martin Baecker, Richard M. Novak, Emmanuel B. Walter, Lisa A. Jackson, Susan J. Little, Lilly C. Immergluck, Siham M. Mahgoub, Jennifer A. Whitaker, Tara M. Babu, Paul A. Goepfert, Dahlene N. Fusco, Robert L. Atmar, Christine M. Posavad, Antonia Netzl, Derek J. Smith, Kalyani Telu, Jinjian Mu, Mat Makowski, Mamodikoe K. Makhene, Sonja Crandon, David C. Montefiori, Paul C. Roberts, John H. Beigel
Summary: In a randomized clinical trial, early neutralizing antibody responses after boosting with bivalent SARS-CoV-2 mRNA vaccines based on either BA.1 or BA.4/BA.5 Omicron spike protein combined with wild-type spike were compared. Both bivalent vaccines showed the greatest reduction in titers against currently circulating Omicron subvariants.
CLINICAL INFECTIOUS DISEASES
(2023)
Article
Immunology
Anoma Nellore, Esther Zumaquero, Christopher D. Scharer, Christopher F. Fucile, Christopher M. Tipton, R. Glenn King, Tian Mi, Betty Mousseau, John E. Bradley, Fen Zhou, Stuti Mutneja, Paul A. Goepfert, Jeremy M. Boss, Troy D. Randall, Ignacio Sanz, Alexander F. Rosenberg, Frances E. Lund
Summary: Seasonal influenza vaccination induces different populations of hemagglutinin (HA)-specific memory B (Bmem) cells, characterized by the expression of surface marker FcRL5 and transcriptional factor T-bet. FcRL5+T-bet+ Bmem cells exhibit effector-like memory properties, while T-betnegFcRL5neg Bmem cells have stem-like central memory properties. FcRL5+ Bmem cells are primed for antibody production and differentiate more rapidly into antibody-secreting cells (ASCs) in vitro. The presence of T-bet+ Bmem cells predicts long-lasting humoral immunity and is associated with the secondary immune response to repeat vaccination, indicating their importance in influenza vaccine durability.
Letter
Health Care Sciences & Services
Matthew Zirui Tay, Yun Shan Goh, Siew-Wai Fong, Zi Wei Chang, Angeline Rouers, Nathan Wong, Anthony Torres-Ruesta, Yuling Huang, Sooriya Kannan Selvam, Pei Xiang Hor, Chiew Yee Loh, Bei Wang, Siti Nazihah Mohd Salleh, Eve Zi Xian Ngoh, Raphael Tze Chuen Lee, Vanessa Neo, Isaac Kai Jie Kam, Xuan Ying Poh, Suma Rao, Po Ying Chia, Sean W. X. Ong, Tau Hong Lee, Clarissa Lim, Jefanie Teo, Sebastian NCID Study Grp, Cheng-I PRIBIVAC Cohort Study Grp, Sebastian Maurer-Stroh, Cheng- Wang, Yee-Sin Leo, Raymond Tzer Pin Lin, David C. Lye, Barnaby Edward Young, Lisa F. P. Ng, Laurent Renia
LANCET REGIONAL HEALTH-WESTERN PACIFIC
(2023)
Article
Immunology
Nadine G. Rouphael, Angela R. Branche, David J. Diemert, Ann R. Falsey, Cecilia Losada, Lindsey R. Baden, Sharon E. Frey, Jennifer A. Whitaker, Susan J. Little, Satoshi Kamidani, Emmanuel B. Walter, Richard M. Novak, Richard Rupp, Lisa A. Jackson, Tara M. Babu, Angelica C. Kottkamp, Anne F. Luetkemeyer, Lilly C. Immergluck, Rachel M. Presti, Martin Backer, Patricia L. Winokur, Siham M. Mahgoub, Paul A. Goepfert, Dahlene N. Fusco, Robert L. Atmar, Christine M. Posavad, Antonia Netzl, Derek J. Smith, Kalyani Telu, Jinjian Mu, Lisa J. McQuarrie, Mat Makowski, Mamodikoe K. Makhene, Sonja Crandon, David C. Montefiori, Paul C. Roberts, John H. Beigel, Kuleni Abebe
Summary: A comparison was conducted on the serologic responses in adults between a single dose and a two-dose variant vaccine (Moderna mRNA-1273 Beta/Omicron BA.1 bivalent vaccine). The findings indicate that a two-dose boosting regimen with a variant vaccine does not enhance the magnitude or durability of the serological responses compared to a single variant vaccine boost.
JOURNAL OF INFECTIOUS DISEASES
(2023)
Article
Genetics & Heredity
Margaret G. Guo, David L. Reynolds, Cheen E. Ang, Yingfei Liu, Yang Zhao, Laura K. H. Donohue, Zurab Siprashvili, Xue Yang, Yongjin Yoo, Smarajit Mondal, Audrey Hong, Jessica Kain, Lindsey Meservey, Tania Fabo, Ibtihal Elfaki, Laura N. Kellman, Nathan S. Abell, Yash Pershad, Vafa Bayat, Payam Etminani, Mark Holodniy, Daniel H. Geschwind, Stephen B. Montgomery, Laramie E. Duncan, Alexander E. Urban, Russ B. Altman, Marius Wernig, Paul A. Khavari
Summary: Noncoding variants play a role in the heritability of neuropsychiatric diseases. A study in developing human neural cells investigated 2,221 noncoding variants associated with ten neuropsychiatric disorders and identified differentially-active single-nucleotide variants (daSNVs) in specific neural cell types. Integrating epigenomic and transcriptomic data helped identify candidate disease-relevant target genes modulated by these daSNVs.
Article
Microbiology
Karla M. Tamez-Torres, Norma Mongua-Rodriguez, Leticia Ferreyra-Reyes, Pedro Torres-Gonzalez, Guadalupe Delgado-Sanchez, Maribel Martinez-Hernandez, Miriam Bobadilla-del-Valle, Velma Y. Jasso-Sosa, Priscila del S. Lopez-Castillo, Elizabeth Ferreira-Guerrero, Luis Pablo Cruz-Hervert, Jose Sifuentes-Osornio, Carlos A. Aguilar-Salinas, Lourdes Garcia-Garcia, Alfredo Ponce-de-Leon
Summary: Tuberculosis (TB) associated with diabetes mellitus (DM) is a growing problem, particularly in low- and medium-resource countries. However, the use of isoniazid (INH) or rifampicin (RIF) for TB preventive treatment (TPT) in people with type 2 DM is not safe enough to be considered a universal indication.
Article
Microbiology
Fabian Rojas-Larios, Bernardo Alfonso Martinez-Guerra, Luis Esau Lopez-Jacome, Enrique Bolado-Martinez, Maria del Rosario Vazquez-Larios, Maria del Consuelo Velazquez-Acosta, Daniel Romero-Romero, Christian Daniel Mireles-Davalos, Sandra Quintana-Ponce, Jose Manuel Feliciano-Guzman, Jose Miguel Perez-Hernandez, Yoselin Paola Correa-Leon, Eduardo Lopez-Gutierrez, Eduardo Rodriguez-Noriega, Esteban Gonzalez-Diaz, Elena Victoria Choy-Chang, Juan Pablo Mena-Ramirez, Victor Antonio Monroy-Colin, Alfredo Ponce-de-Leon-Garduno, Margarita Alcaraz-Espejel, Laura Karina Aviles-Benitez, Luis Javier Quintanilla-Cazares, Eloisa Ramirez-Alanis, Juan Manuel Barajas-Magallon, Cecilia Padilla-Ibarra, Maria Bertha Ballesteros-Silva, Noe Antonio Atanacio-Sixto, Cecilia Teresita Morales-de-la-Pena, Mario Galindo-Mendez, Talia Perez-Vicelis, Guillermo Jacobo-Baca, Martha Irene Moreno-Mendez, Maria de la Luz Mora-Pacheco, Maricruz Gutierrez-Brito, Xochitl Yadira Sanchez-Godinez, Norberta Vianey Navarro-Vargas, Luz Elena Mercado-Bravo, Alejandro Delgado-Barrientos, Maria Asuncion Santiago-Calderon, Ismelda Lopez-Ovilla, Alejandro Molina-Chavarria, Joaquin Rincon-Zuno, Rafael Franco-Cendejas, Sandra Miranda-Mauricio, Isabel Cristina Marquez-Avalos, Maribel Lopez-Garcia, Lizbeth Soraya Duarte-Miranda, Carlos Miguel Cetina-Umana, Irma Elena Barroso-Herrera-y-Cairo, Laura Isabel Lopez-Moreno, Elvira Garza-Gonzalez
Summary: We analyzed antimicrobial resistance (AMR) data of clinical isolates from 43 centers in Mexico, including Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterococcus faecium, and Staphylococcus aureus. The study investigated the site of care, patient age, and clinical specimen type to determine AMR patterns. The findings revealed that ICU patients had the highest AMR in E. coli, K. pneumoniae, and P. aeruginosa isolates, while non-ICU patients had higher AMR in A. baumannii isolates. The oldest age group showed the highest AMR in E. coli, E. faecium, and S. aureus, while the 19-59 age group had the highest AMR in A. baumannii and P. aeruginosa. Additionally, higher AMR was observed in E. coli, K. pneumoniae, and P. aeruginosa isolates from blood specimens, and the most frequently detected carbapenemase-encoding gene in E. coli was blaNDM (84%).
Article
Infectious Diseases
Hector Orlando Rivera-Villegas, Bernardo Alfonso Martinez-Guerra, Rosalia Garcia-Couturier, Luis Fernando Xancal-Salvador, Veronica Esteban-Kenel, Ricardo Antonio Jaimes-Aquino, Miguel Mendoza-Rojas, Axel Cervantes-Sanchez, Steven Mendez-Ramos, Jorge Eduardo Alonso-Montoya, Diana Munguia-Ramos, Karla Maria Tamez-Torres, Carla Marina Roman-Montes, Sandra Rajme-Lopez, Areli Martinez-Gamboa, Miriam Bobadilla-del-Valle, Maria Fernanda Gonzalez-Lara, Jose Sifuentes-Osornio, Alfredo Ponce-de-Leon
Summary: This study aimed to identify factors associated with 90-day all-cause mortality in patients with CR-GNB infections. The results showed that age, immunosuppression, and septic shock at diagnosis were independently associated with death within 90 days after CR-GNB infection. Additionally, receiving antibiogram-guided appropriate treatment was independently associated with a lower risk of death. These findings have important implications for clinical practice and addressing the problem of carbapenem resistance.
Article
Pediatrics
Chee Fu Yung, Deanette Pang, Kai Qian Kam, David C. Lye, Benjamin Ong, Chia Yin Chong, Kelvin B. Tan
Summary: This study aimed to investigate the level of protection provided by the BNT162b2 COVID-19 vaccine against Omicron variant infection in children and the impact of previous variant-specific infection on vaccine effectiveness. The study found that the vaccine provided 74-85.7% protection against BA.4 or BA.5 infection and 47.9-62.8% protection against XBB infection. The sequence of previous infection had an influence on vaccine effectiveness.
LANCET CHILD & ADOLESCENT HEALTH
(2023)
Article
Immunology
Tomas O. Jensen, Greg A. Grandits, Mamta K. Jain, Thomas A. Murray, Birgit Grund, Kathryn Shaw-Saliba, Michael A. Matthay, Mahsa Abassi, Magdalena Ardelt, Jason V. Baker, Peter Chen, Robin L. Dewar, Anna L. Goodman, Timothy J. Hatlen, Helene C. Highbarger, Mark Holodniy, Perrine Lallemand, Sylvain Laverdure, Bradley G. Leshnower, David Looney, Charalampos D. Moschopoulos, Henry Mugerwa, Daniel D. Murray, Eleftherios Mylonakis, Stephanie Nagy-Agren, M. Tauseef Rehman, Adam Rupert, Randy A. Stevens, Stuart Turville, Amy Weintrob, Katherine Wick, Jens Lundgren, Emily R. Ko
Summary: This study suggests that neutralizing monoclonal antibodies have an antiviral effect among hospitalized patients with COVID-19, without affecting the endogenous anti-nucleocapsid antibody response, systemic inflammation, or clinical status on day 5.
JOURNAL OF INFECTIOUS DISEASES
(2023)
Article
Immunology
Yun Shan Goh, Siew-Wai Fong, Pei Xiang Hor, Chiew Yee Loh, Bei Wang, Siti Nazihah Mohd Salleh, Eve Zi Xian Ngoh, Raphael Tze Chuen Lee, Xuan Ying Poh, Suma Rao, Po Ying Chia, Sean W. X. Ong, Tau Hong Lee, Clarissa Lim, Jefanie Teo, Surinder Pada, Louisa Jin Sun, Desmond Luan Seng Ong, Jyoti Somani, Eng Sing Lee, Sebastian Maurer-Stroh, Cheng- Wang, Yee-Sin Leo, David C. Lye, Barnaby Edward Young, Lisa F. P. Ng, Laurent Renia
Summary: This study found that individuals with a higher variant-specific IgA antibody response one month after booster vaccination were associated with a lower risk of infection. Individuals who remained uninfected for at least 8 months had higher variant-specific IgA levels compared to those who became infected.
JOURNAL OF INFECTIOUS DISEASES
(2023)
Article
Immunology
Jordan Cates, Cristina Cardemil, Sara A. Mirza, Ben Lopman, Aron J. Hall, Mark Holodniy, Cynthia Lucero-Obusan
Summary: Norovirus infection was associated with a slight increased risk of hospitalization and significant increased risk of mortality within 3 days of norovirus diagnosis among a large national cohort of US veterans.
OPEN FORUM INFECTIOUS DISEASES
(2023)